LoginSignup
Crispr Therapeut logo

Crispr Therapeut

Stock
Stock
ISIN: CH0334081137
Ticker: CRSP
CH0334081137
CRSP

Price

Price

CHART BY

Frequently asked questions

What is Crispr Therapeut's market capitalization?

The market capitalization of Crispr Therapeut is $3.48B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Crispr Therapeut?

Crispr Therapeut's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.824. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Crispr Therapeut's stock?

Currently, 31 analysts cover Crispr Therapeut's stock, with a consensus target price of $78.50. Analyst ratings provide insights into the stock's expected performance.

What is Crispr Therapeut's revenue over the trailing twelve months?

Over the trailing twelve months, Crispr Therapeut reported a revenue of $202.83M.

What is the EBITDA for Crispr Therapeut?

Crispr Therapeut's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$313.02M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Crispr Therapeut?

Crispr Therapeut has a free cash flow of -$191.20M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Crispr Therapeut have, and what sector and industry does it belong to?

Crispr Therapeut employs approximately 407 people. It operates in the Health Care sector, specifically within the Biotechnology industry.

What is the free float of Crispr Therapeut's shares?

The free float of Crispr Therapeut is 81.70M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$3.48B
EPS (TTM) 
-$2.824
Free Float 
81.70M
Revenue (TTM) 
$202.83M
EBITDA (TTM) 
-$313.02M
Free Cashflow (TTM) 
-$191.20M

Pricing

1D span
$39.29$40.74
52W span
$39.49$91.05

Analyst Ratings

The price target is $78.50 and the stock is covered by 31 analysts.

Buy

16

Hold

13

Sell

2

Information

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Employees
407
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
CH0334081137
Primary Ticker
CRSP

Knockouts

Join the conversation
Sign upLogin